BeOne Medicines (ONC) Leases (2017 - 2026)

BeOne Medicines (ONC) has 10 years of Leases data on file, last reported at $145.5 million in Q1 2026.

• Quarterly Leases fell 0.63% year-over-year to $145.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $145.5 million (down 0.63% YoY) and the FY2025 annual result came in at $148.2 million, up 6.37% from the prior year.
• Leases declined to $145.5 million in Q1 2026 per ONC's latest filing, from $148.2 million in the prior quarter.
• Across five years, Leases topped out at $148.2 million in Q4 2025 and bottomed at $87.7 million in Q1 2024.
• The 5-year median for Leases is $110.3 million (2022), against an average of $118.4 million.
• The widest annual swing landed in 2024, when Leases decreased 19.49%; it then jumped 66.86% in 2025.
• Tracing ONC's Leases over 5 years: stood at $110.0 million in 2022, then declined by 13.42% to $95.2 million in 2023, then jumped by 46.32% to $139.3 million in 2024, then grew by 6.37% to $148.2 million in 2025, then slipped by 1.81% to $145.5 million in 2026.
• Per Business Quant, the three latest ONC Leases figures stand at $145.5 million (Q1 2026), $148.2 million (Q4 2025), and $140.2 million (Q3 2025).

Peer Comparison